Viage Therapeutics Inc.
viagetx.com
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
2
Kyoto University Innovation Capital, Miyako Capital
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2018
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Kyoto University Innovation Capital 
Miyako Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
EX-Fusion is a Japanese deep-tech startup working to realise a commercial laser fusion reactor. It develops the technology needed for laser…
BabySensor is developing a new unique monitor that measures the most important factors for a baby's health and well-being. It is the only…
Ai.io is a ground-breaking, award-winning sports AI technology & data company, that develops AI & technology solutions across all sport.
The future ofearly cancer detection is now. A ground breaking AI-enabled early detection platform focused on women's health.
GlycoLogix - A ground-breaking therapy for Interstitial Cystitis / Bladder Pain Syndrome, developing biopolymers for soft tissue repair.
Starlight Engine is a Japanese fusion energy company working toward the practical use of fusion power to solve energy problems. A…
Overview
About. Viage Therapeutics, a neuroscience company based on a platform of novel neurotherapeutics, was founded in 2018. The company is based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University.
News
Viage Therapeutics announces data from a Phase 1 study with DGX-001, a first-in-class oral neurotherapeutic targeting cognitive impairment in patients with Alzheimer's Disease and Parkinson's Disease
Viage Therapeutics (Viage), a neuroscience company based on a platform of novel neurotherapeutics, today announced positive findings from its Phase 1 study of DGX-001, a first-in class oral therapeutic targeting the AVPR1A receptor in the gut. DGX-001 dem
Read more
Report
Digestome Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of DGX-001
Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system (CNS) via the gut-brain-axis, announced that the first patient has been enrolled in a Phase 1 clinical trial investigating DGX-001.
Read more
Report
Digestome Therapeutics Announces Exclusive Out-license of DGX-001 for Greater China with Zhongze Therapeutics
Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system (CNS) via the gut-brain-axis, announced today the completion of an exclusive out-licensing agreement of DGX-001 in the greater China
Read more
Report
Digestome Therapeutics Completes $10 Million Seed Financing
Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate mind via the gut-brain-axis, announced today the completion of a $10M Seed financing to advance its lead program into clinical trials starting early 2022.
Read more
Report
Hey, There's a Second Brain in Your Gut
New research reveals that the "second brain" in your gut has at least a dozen kinds of neurons, unlocking new paths to further experiments and findings.
Read more
Report
How Your Gut Influences Your Mental Health: It's Practically a Second Brain
Dr. Emeran Mayer discusses the mind-gut connnection.
Read more
Report